Squarepoint
IRD

Squarepoint’s Opus Genetics IRD Stock Holding History

Squarepoint’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.36M Buy
+330,783
New +$1.54M ﹤0.01% 2646
2024
Q1 		– Sell
-61,152
Closed -$184K – 4715
2023
Q4 		$184K Buy
61,152
+1,042
+2% +$3.08K ﹤0.01% 3628
2023
Q3 		$201K Buy
60,110
+25,278
+73% +$102K ﹤0.01% 3408
2023
Q2 		$151K Buy
+34,832
New +$165K ﹤0.01% 3285
2022
Q1 		– Sell
-10,655
Closed -$40K – 3645
2021
Q4 		$40K Buy
+10,655
New +$42.7K ﹤0.01% 3053
2021
Q3 		– Sell
-19,395
Closed -$102K – 3525
2021
Q2 		$102K Buy
19,395
+9,030
+87% +$44.8K ﹤0.01% 3010
2021
Q1 		$60K Sell
10,365
-9,207
-47% -$85.5K ﹤0.01% 2977
2020
Q4 		$127K Buy
+19,572
New +$135K ﹤0.01% 2665

Other funds holding IRD

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Squarepoint's IRD Position: Q2 2026 in Review

Squarepoint opened a new position in Opus Genetics (IRD) in Q2 2026: 330,783 shares worth $1.36M. The stake represents ﹤0.01% of the portfolio and ranks #2646 among its holdings. This is a return to the name: Squarepoint previously reported a position in IRD as recently as Q4 2023.

Squarepoint first reported a position in IRD in Q4 2020 and has held it in 8 quarters since. 103 funds tracked by Wall St. Rank hold IRD as of Q2 2026.

  • Squarepoint held 330,783 shares of Opus Genetics worth $1.36M as of Q2 2026.
  • Opus Genetics was a new Squarepoint position in Q2 2026.
  • Opus Genetics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2646 holding.
  • Squarepoint first reported a position in Opus Genetics in Q4 2020 and has held it in 8 quarters since.
  • 103 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.